Document |
Document Title |
WO/2005/086974A2 |
The invention provides compounds and methods for treating cancer. Exemplary compounds are multi-functional compounds with two different moieties connected by a linker. Compounds of the invention can activate one or more pathways that res...
|
WO/2005/070950A1 |
The present invention is a di-steroidal prodrug of ethinyl estradiol according to formula (I)
|
WO/2005/070951A1 |
A method is provided for preparing an aromatase inhibitor of formula (I) wherein each of R1, R2, R3, R4, independently, is hydrogen, halogen or Cl-C6 alkyl. In one form, the aromatase inhibitor is exemestane wherein each of R1, R2, R3, R...
|
WO/2005/070949A1 |
The present invention is a di-steroidal prodrug of estradiol having formula (I).
|
WO/2005/066114A1 |
The present invention relates to cornpounds of the formula (I) or (II) or pharmaceutically acceptable salts thereof useful for the prophylaxis and treatment of degenerative bone disorders and for the acceleration of bone healing.
|
WO/2005/066194A1 |
Compounds having the structure or their salts: are used to treat or reduce le likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, sebor...
|
WO/2005/051972A1 |
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for t...
|
WO/2005/048956A2 |
This invention relates to new estradiol-related compounds that can be used to treat various types of cancer including prostate and breast cancers.
|
WO/2005/047303A2 |
The present invention relates to novel 3, 15 substituted estrone derivatives which represent inhibitory compounds of the 17β-hydroxysteroid dehydrogenase type I (17β-HSD1), to their salts, to pharmaceutical preparations containing thes...
|
WO/2005/032560A2 |
Disclosed herein is the method for separation of enantiomers or isomers of digoxin. These isomers are to be used in the treatment of heart failure without adverse or unneeded cardiac actions in humans. Additionally what is claimed is an ...
|
WO/2005/030120A2 |
Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula (I) wherein the variables are defined in the specification.
|
WO/2005/030790A1 |
The present invention relates to novel synthetic derivatives of triterpenes and the use of such derivatives as pharmaceuticals. In some embodiments, the present invention is directed to the use of derivatives of triterpenes of the presen...
|
WO2002042319A9 |
Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula (I), wherein the variables are defined in the specification.
|
WO/2005/026083A2 |
Described are drug formulations that increase regional delivery of the drugs to cells. Methods for reversibly increasing the hydrophobicity of a drug through hydrolytically labile attachment of a hydrophobic moiety and methods for delive...
|
WO/2005/010021A1 |
The invention relates to a method for obtaining an extract which contains the natural mixture of conjugated equine estrogens, whereby the mixture of conjugated estrogens, which is obtained by solid phase extraction from the pregnant mare...
|
WO/2005/005451A1 |
A compound of formula (I): (I) wherein X represents O or S; R1 represents C1-6 alkyl, C3-8 cycloalkyl, C3-8 cycloalkylmethyl or C3-8 cycloalkenyl any of which optionally may be substituted by one or more methyl groups or halogen atoms or...
|
WO/2005/005452A1 |
A compound of formula (I): or a physiologically acceptable solvate thereof.
|
WO/2005/005449A2 |
The invention pertains to steroid modified solatrioses and the synthesis thereof as well as to intermediate compounds useful for the synthesis of the steroid modified solatrioses.
|
WO/2005/003148A1 |
The present invention relates to a two part microbial process for the preparation of 7-oxo-5-androstene steroids of Formula III.
|
WO2003102012A9 |
The subject invention provides new progestogen esters and uses thereof.
|
WO/2005/000868A1 |
The invention relates to a process for the synthesis of high purity d-(17&agr )-13-ethyl-17hydroxy-18,19-dinorpregn-4-ene-20-yne-3-one-o
xime (further on norelgestromine) via acetylation of d-norgestrel at position 17, oximation of the...
|
WO/2005/000245A2 |
The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The methods and compositions are useful f...
|
WO/2004/106358A1 |
The invention relates to dialkyltriazene-supporting estrogens and antiestrogens that are suited for use as chemotherapeutic drugs for treating carcinomas of the sexual organs of humans and animals.
|
WO/2004/098538A2 |
The invention describes novel nitrosated and/or nitrosylated compounds of the invention, and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated compound of the inventi...
|
WO/2004/096829A2 |
The invention relates to a method of preparing compounds having general formula (I), wherein: R1, R2, R3, n and X are as defined in the description. The invention also relates to the intermediate compounds used to implement said method.
|
WO/2004/094449A1 |
The present invention relates to new compounds represented by Formula (I); wherein M represents a macrolide subunit of the substructure II, Formula (II); L represents the chain of the substructure III, Formula (III); D represents the ste...
|
WO/2004/094451A2 |
The invention relates to 8β-vinyl-11β-(&ohgr -substituted)alkyl-estra-1,3,5(10)-trienes of general formula (I), which have ERβ-antagonistic activity, methods for the production thereof, the intermediate products thereof, pharmaceutica...
|
WO/2004/089971A1 |
Steroidal antiandrogens and pharmaceutical compositions thereof, are used for reduction of the risk of developing, or for treatment of, androgen-dependent skin related diseases. In preferred embodiments, the antiandrogen EM-3180 is used ...
|
WO/2004/089304A2 |
The instant invention provides potent antiandrogen compounds, such as 3β -acetoxyandrost-1,5-diene-17-ethylene ketal and 3β-hydroxyandrost-1, 5-diene-17ethylene ketal, and methods for their use in the prevention and treatment of biolog...
|
WO/2004/085345A2 |
The present invention relates to analogs of estradiol, which, in their most preferred embodiment, act as locally active estrogens without significant systemic action. A series of 15&agr -estradiol ester compounds is presented which exhib...
|
WO/2004/078774A1 |
Disclosed is a process for the synthesis of 17β-hydroxy-7&agr -methyl- 19-nor-17&agr -pregn-5(10)-ene-20-yne-3-one (tibolone, 11) and intermediates useful for the synthesis thereof: (11).
|
WO/2004/074306A1 |
A continuous process for the preparation of 16&agr ,17&agr [(R)butylidenedioxy]-6&agr ,9&agr -difluoro-11β,21-dihydroxypregn-4-ene-3,20-dione (rofleponide) is disclosed.
|
WO/2004/071427A2 |
Provided herein are methods, combinations, and kits for screening and treating a subject. In practicing the methods a sample, such as urine, blood, plasma, saliva, cervical fluid, vaginal fluid, or a tissue sample, is obtained from a sub...
|
WO/2004/067547A2 |
The invention relates to the production and use of novel 14ß-alkyl-18-norsteroids, 8&agr ,14ß-dialkyl-18-norsteroids, spiro[cyclopentano-perhydronaph-thalin]-3,1&grave -pentanes or hexanes in addition to 14ß-fluoro-15ß,17ß-dihydroxy...
|
WO/2004/064722A2 |
The present invention relates to a process for the synthesis of oxandrolone from mestanolone. The process comprises the steps of: (a) oxidizing mestanolone to form 17β -hydroxy-17&agr -methyl-5 -androst-1-en-3-one; (b) hydroxylating the...
|
WO/2004/062606A2 |
Accelerating fat loss by administering to a dieting mammal the fat loss accelerating agent 7-oxo DHEA or a pro-drug thereof incapable of in vivo conversion to testosterone.
|
WO/2004/045560A2 |
The pharmaceutical and/or cosmetic compositions for treatment of obesity and/or overweight contain an effective amount of a fatty-acid monoester of a 2 hydroxy derivative estrogen and a fatty acid wherein the estrogen is preferably a 2 h...
|
WO/2004/043987A1 |
This invention relates to processes for the preparation of 7-carboxy substituted steroid compounds of Formula (I) wherein R1 is selected from H or COR4; R4 is C1-C6 alkyl or C1-C6 alkoxy; R3 is C1-C6 alkyl; Z1 is -CH2- or Formula (II) wh...
|
WO/2004/043986A1 |
This invention relates to processes for the preparation of novel , substituted steroid compounds of Formula 1, wherein R1 is H or. COR2; R2 is C1-C6 alkyl or Ct-C6 alkoxy; Z1 is CH2, or wherein OR3 is in the &agr configuration; R3 is H o...
|
WO/2004/041839A2 |
A process is provided for the making of estetrol starting from a 3-A-oxy-estra 1,3,5(10),15-tetraen-17-one, wherein A is an C1-C5 alkyl group, preferably a methyl group, or a C7 - C12 benzylic group, preferably a benzyl group. This proce...
|
WO2004011663A9 |
Disclosed is a new synthetic pathway for the production of precursors for the production of compounds having general formula (8,10,12). During said synthesis, compounds of general formal (4,B) are produced in a microbiological reaction. ...
|
WO/2004/037173A2 |
The present invention relates to a transdermal hydroalcoholic testosterone gel formulation that overcomes the problems associated with other testosterone delivery mechanisms by providing, among other things, a desirable pharmacokinetic h...
|
WO/2004/037844A1 |
The present invention involves a novel crystal form of 17β-hydroxy-7&agr -(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxyli
c acid, &gammad -lactone (II) which is an intermediate useful in preparation of an important pharmaceu...
|
WO2002101014B1 |
A novel process for making estra-4,9(10)-diene-3,17-dione steroids from readily available 19-nor-androst-4-ene-3-one steroids by a straightforward three-step process. Products of this process are important intermediates in the preparatio...
|
WO/2004/035817A1 |
A method of measuring cholesterol in high-density lipoproteins characterized by comprising reacting a specimen with cholesterol ester hydrolase and cholesterol oxidase, or cholesterol ester hydrolase, an oxidized coenzyme and cholesterol...
|
WO/2004/016640A2 |
The present invention provides 5-androsten-3β-ol steroid intermediates and processes for their preparation.
|
WO/2004/014935A1 |
The invention relates to novel compounds of general formula (I), to the production thereof and to pharmaceutical preparations containing these compounds. The inventive compounds are preferably used in female fertility testing and hormone...
|
WO/2004/014934A2 |
The present invention relates to a new process of synthesis and to some new intermediates for the preparation of steroids with progestogen activity, more particularly, for the preparation of Desogestrel of formula (I). Said process is ch...
|
WO/2004/004634A2 |
A therapy method for treating infertility in a female host, comprising the administration of an ovarian follicular stimulating effective amount of exemestane, is provided.
|
WO/2003/104254A2 |
The present invention provides novel derivatives comprising compounds in the androstane and androstene series, coupled with ascorbic acid, including salts thereof, and represented by one or more of the general formulae (I), (II), (III): ...
|